10. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J. 2020 Jan 1; 41(1): 111-188. 11. 中国胆固醇教育计划(CCEP...
Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS guidelines for the management of dyslipidaemi...
Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058. doi: 10.1093/eurheartj/ehw272. ...
9. Grundy, S. M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC /NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the...
This concept led to a substantial reduction of the LDL-C goals recommended by the most recent guidelines for the management of dyslipidemias (Mach et al. 2020). Statins, which represent the cornerstone for the treatment of hypercholesterolemia, have shown approximately a 20% reduction in the ...
Author(s): Evan A Stein [1] A role for cholesterol in coronary artery disease (CAD) was postulated for nearly a century before sufficient evidence from clinical trials became available in the mid-1980s to include it in prevention guidelines. LDL-cholesterol (LDL-C) reduction is now the ...
Compliance with Ethics Guidelines ᅟ Conflict of Interest Bernd Hewing declares that he has no conflict of interest. Ulf Landmesser has received lecture and/or advisory honoraria or research grant support from Pfizer, Roche, MSD, Sanofi, and Amgen. ...
The objective of the present study was to investigate the prevalence of elevated Lp(a) levels in a population of patients with CAD and how they impact LDL-C concentrations and the achievement of the LDL-C goals set forth in the guidelines for very high-risk CAD patients. ...
The primary therapy for low HDL-C is lifestyle modification. In patients requiring drug therapy to lower LDL-C, the guidelines recommend selecting an agent that will also increase HDL-C, and in CAD patients with low HDL-C, the guidelines suggest the initiation of niacin even if LDL-C is ...
(Figure 1;Pfor trend=0.008). Patients seen at practices in urban locations were more likely to undergo lipid testing than at practices in rural locations (65.5% versus 44.5%;P<0.001). Patients seen by providers who re...